Literature DB >> 9597150

Cyclooxygenases 1 and 2.

J R Vane1, Y S Bakhle, R M Botting.   

Abstract

Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2. However, COX-2 was inducible, and the inducing stimuli included pro-inflammatory cytokines and growth factors, implying a role for COX-2 in both inflammation and control of cell growth. The two isoforms of COX are almost identical in structure but have important differences in substrate and inhibitor selectivity and in their intracellular locations. Protective PGs, which preserve the integrity of the stomach lining and maintain normal renal function in a compromised kidney, are synthesized by COX-1. In addition to the induction of COX-2 in inflammatory lesions, it is present constitutively in the brain and spinal cord, where it may be involved in nerve transmission, particularly that for pain and fever. PGs made by COX-2 are also important in ovulation and in the birth process. The discovery of COX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1. These highly selective COX-2 inhibitors may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597150     DOI: 10.1146/annurev.pharmtox.38.1.97

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  514 in total

1.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Authors:  Y Matsuoka; M Picciano; B Malester; J LaFrancois; C Zehr; J M Daeschner; J A Olschowka; M I Fonseca; M K O'Banion; A J Tenner; C A Lemere; K Duff
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

Review 3.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

5.  Virus self-improvement through inflammation: no pain, no gain.

Authors:  Edward S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

6.  Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking.

Authors:  C N Serhan; C B Clish
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 7.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

8.  Endoplasmic reticulum stress (ER-stress) by 2-deoxy-D-glucose (2DG) reduces cyclooxygenase-2 (COX-2) expression and N-glycosylation and induces a loss of COX-2 activity via a Src kinase-dependent pathway in rabbit articular chondrocytes.

Authors:  Seon-Mi Yu; Song-Ja Kim
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

9.  Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.

Authors:  Henriqueta Coimbra Silva; Vera Alves; Luis Alcides Mesquita Nogueira; Manuel Santos Rosa; Lina Carvalho; Fernando Regateiro
Journal:  Med Oncol       Date:  2011-06-03       Impact factor: 3.064

10.  Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.

Authors:  I Dey; M A Giembycz; K Chadee
Journal:  Br J Pharmacol       Date:  2009-01-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.